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Abstract
Background: KLK15 over-expression is reported to be a significant predictor of reduced progression-free survival
and overall survival in ovarian cancer. Our aim was to analyse the KLK15 gene for putative functional single
nucleotide polymorphisms (SNPs) and assess the association of these and KLK15 HapMap tag SNPs with ovarian
cancer survival.
Results: In silico analysis was performed to identify KLK15 regulatory elements and to classify potentially functional
SNPs in these regions. After SNP validation and identification by DNA sequencing of ovarian cancer cell lines and
aggressive ovarian cancer patients, 9 SNPs were shortlisted and genotyped using the Sequenom iPLEX Mass Array
platform in a cohort of Australian ovarian cancer patients (N = 319). In the Australian dataset we observed
significantly worse survival for the KLK15 rs266851 SNP in a dominant model (Hazard Ratio (HR) 1.42, 95% CI 1.02-
1.96). This association was observed in the same direction in two independent datasets, with a combined HR for
the three studies of 1.16 (1.00-1.34). This SNP lies 15bp downstream of a novel exon and is predicted to be
involved in mRNA splicing. The mutant allele is also predicted to abrogate an HSF-2 binding site.
Conclusions: We provide evidence of association for the SNP rs266851 with ovarian cancer survival. Our results
provide the impetus for downstream functional assays and additional independent validation studies to assess the
role of KLK15 regulatory SNPs and KLK15 isoforms with alternative intracellular functional roles in ovarian cancer
survival.
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Background
Ovarian cancer is an aggressive disease with high meta-
static potential and is frequently diagnosed at an
advanced stage [1,2]. In vitro studies show that malig-
nant cells synthesize and secrete proteolytic enzymes
which disrupt basement and extracellular membranes to
allow malignant cells to invade neighboring tissues and
metastasize [3]. Members of the Kallikrein-related (KLK)
peptidase family are part of a proteolytic enzymatic cas-
cade activated in aggressive forms of hormone-related
cancers including ovarian cancer [4-6]. The KLKs are
encoded by a 15-member gene family clustered together
in a region of approximately 320 kb on chromosome
19q13.4 [5-7]. KLK15 (encoding for KLK15, previously
reported as hK15, or prostinogen) is the most recently
cloned member of the human kallikrein gene family [8],
sharing a high degree of structural similarity with KLK3
(PSA), and is positioned adjacent to the KLK3 gene
[5,8]. KLK15 mRNA expression levels are up-regulated
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addition, KLK15 mRNA expression is reported to be a
favorable diagnostic marker for breast cancer [13], and a
significant predictor of reduced progression-free survival
and overall survival after ovarian cancer diagnosis [12].
Several studies have been undertaken investigating the
role of KLK genetic variants in different cancers, aiming
to better understand cancer biology and also to identify
potential new targets for genetic testing with regard to
cancer risk and prognosis [14-17]. Of note, we have
recently identified a PSA promoter SNP to be associated
with ovarian cancer survival (O’Mara, manuscript sub-
mitted), however, no studies have been undertaken to
a s s e s st h er o l eo fKLK15 genetic variation in ovarian
cancer prognosis.
We used in silico approaches for data mining of the
KLK15 gene for potential functional motifs and differen-
tial splicing to determine regions of the gene that could
be functionally compromised by genetic variations. This
was supplemented by identification of potentially func-
tional common SNPs using database searches and re-
sequencing of ovarian cancer cell lines and patients, to
prioritize variants for ovarian cancer prognosis studies.
We then assessed the association between ovarian can-
cer survival and 9 SNPs tagging 22 prioritized KLK15
SNPs in an Australian dataset, and undertook replica-
tion studies in two other ovarian cancer studies to vali-
date our findings.
Methods
Study Participants and Genotyping
The initial phase of this study included 319 Australian
women diagnosed with primary invasive epithelial ovar-
ian cancer between 1985 and 1997. Over half of the
women (N = 207, 65%) had participated in a large popu-
lation-based case-control study of the etiology of ovarian
cancer. Briefly, these women were ascertained through
major gynecology-oncology treatment centres in the
three most populous Australian states: Queensland, New
SouthWales and Victoria. A central gynecologic histo-
pathologist reviewed all pathology reports and sections
of each tumor to confirm the diagnosis and histological
subtype. The remaining women (N = 112, 35%) were
ascertained as consecutive incident cases from the Royal
Brisbane Hospital (RBH), Queensland, Australia. The
patients in the study were included on the basis on
availability of DNA and survival/follow up data. Infor-
mation on diagnosis, disease stage (using the Interna-
tional Federation of Gynecologists and Obstetricians
[FIGO] criteria), tumor histology and grade was
abstracted retrospectively from the women’s medical
records and pathology reports or, for a subset of cases,
from the RBH Gynecology Oncology database. Full
details of the methods and the characteristics of the
cases have been reported previously [15,18]. The women
were followed for mortality using personal identifiers
which were linked to the Australian National Death
Index (NDI), State Cancer Registry records and the RBH
Gynecology Oncology database. DNA was extracted as
described in previous studies [15,18] and genotyping of
the KLK15 SNPs was performed using the Sequenom
iPLEX MassArray platform (San Diego, CA, USA)
according to manufacturer instructions. The first repli-
cation sample set included 1815 patients from the stage
1 of an ovarian cancer genome-wide association study
(GWAS), all with confirmed invasive epithelial ovarian
cancer from four different ovarian cancer case series in
the United Kingdom (UK): United Kingdom Ovarian
Population study (UKOPS), Study of Epidemiology and
Risk Factors in Cancer Heredity (SEARCH), Royal Mars-
den Hospital (RMH) and United Kingdom Familial
Ovarian Cancer Registry (UKFOCR), as described pre-
viously [19]. Genotyping of the replication sample set
was performed as part of the first published genome-
wide association study (GWAS) of ovarian cancer [19].
The second replication dataset consisted of 413
women with invasive epithelial ovarian cancer from The
Cancer Genome Atlas (TCGA) Pilot Project established
by the National Cancer Institute and the National
Human Genome Research Institute. Information about
TCGA and the investigators and institutions that consti-
tute the TCGA research network can be found at their
website [20]. Genotyping and clinical data for ovarian
cancer patients were downloaded via the TCGA data
portal.
Progression-free survival, residual disease status and
platinum sensitivity data were not available for the Aus-
tralian or European sample sets. Informed consent was
obtained from all the participating subjects. Human
Ethics Committee approval was given for the recruit-
ment and genotyping of all the individuals included in
this study.
Web based search for putative splice-variants
Access information for the KLK15 gene and its protein
product was downloaded from different databases as
given in Additional file 1. Potential KLK15 alternative
splice variants were identified through sequence align-
ment analysis of the splice variants and Expression
Sequence Tags (ESTs) reported in publicly available
databases including NCBI and Ensembl. Sequence align-
ments were performed using the clustal W platform.
SignalP 3.0 Server and PSORT II Prediction default
matrices were used to determine if each KLK15 isoform
contained a signal peptide. mRNA folding of all the
KLK15 variants was analysed by in silico modeling using
mfold version 2.3. Additional file 2 details the websites
used for the in silico analysis.
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The 11 kb region upstream of exon 1 on chromosome
19 (56020307 to 56037591 bp, NCBI build 36.3) along
with the KLK15 coding sequence (Ensemble ID;
ENSGG000000174562) was selected for putative promo-
ter and SNP analysis using websites in Additional file 2.
In brief, WWW Promoter Scan, PromoterInspector,
CpG Islands, and Cister were used to predict and ana-
lyse putative promoter regions. Since hormonal steroids
a r ek n o w nt ob ek e yr e g u l a t o r so fKLK expression in
hormone dependent cancers [21,22], we assessed the
promoter regions for putative estrogen and androgen
regulatory elements. Dragon ERE finder (sensitivity of
0.83) and Cister (ERE matrix) were used to find putative
estrogen response elements (EREs). Cister (ARE matrix)
and JASPAR (threshold 75%) were used to identify puta-
tive androgen response elements (AREs). SIFT and Poly-
phen were used to predict the functional significance of
non-synonymous SNPs (nsSNPS). Webserver FastSNP
was used for predicting the functional significance of
the UTR and splice site SNPs. Analysis for putative
microRNA (miRNA) sites was performed using miRBase
Targets V4, Target scan, miRanda, PicTar and Patrocles.
Cell culture, RT PCR and sequencing of KLK15 putative
promoter region
The normal ovarian cell line HOSE17.1 and serous
epithelial ovarian carcinoma cell lines OVCA432,
SKOV3, PEO1 were cultured as previously described
[15]. RNA extraction and reverse transcription-PCR
(RT-PCR) were performed as previously published [15].
Briefly, RNA was isolated using the RNAeasy kit (Qia-
gen), treated with DNaseI (Invitrogen), and 2 μgR N A
reverse-transcribed using Superscript III™ (Invitrogen).
PCR was performed with primers (K15ExBFor,
5’-TTCAAGACCCCCAGATGGAGAAAAG-3’ and
K15Ex2Rev, 5’-CTTCCAGCAACTTGTCACCA-3’)f o r
35 cycles with conditions of 94°C for 5 min followed by
35 cycles of 94°C, 64°C and 72°C for 1 min each, and a
final extension at 72°C for 10 min. PCR for b2-micro-
globulin was used as an internal control. The PCR pro-
ducts were visualised by electrophoresis on 1.5% agarose
gels stained with ethidium bromide. Genomic DNA was
extracted using QIAamp DNA Mini Kit (Qiagen, Hilde,
Germany). Four primer sets (Additional file 3) were
designed using NETprimer http://www.premierbiosoft.
com/netprimer/index.html to amplify segments of the
putative KLK15 promoter region with the greatest den-
sity of likely functional SNPs, based on results from the
in silico analysis. All reactions (20 uL) contained 10 ng
o fg e n o m i cD N A ,0 . 2 5u Mo fe a c hr e g i o ns p e c i f i cp r i -
mer (Proligo, Lismore, NSW, Australia), 0.2 mM dNTP
mix (Roche, Castle Hill, NSW, Australia), 0.03 mM
Magnesium Chloride (Invitrogen, Victoria, Australia).
Denaturing agents DMSO and betaine (Sigma) were
added to destabilize secondary structures in the tem-
plate, and improve both the PCR and sequencing qual-
ity. PCR products were sequenced at the Australian
Genome Research Facility (AGRF, Brisbane, Australia)
using dideoxy dye chain-termination technology
(Applied Biosystems). Sequences were aligned and ana-
lyzed using SeqMan™II (DNASTAR, WI, USA).
Statistical Analysis
Survival time was calculated from date of diagnosis to
date of death (from ovarian cancer) or censored at
1 September, 2004 or death from another cause. The
Kaplan-Meier technique was used to estimate crude
overall survival probabilities, and adjusted hazard ratios
(HR) and 95% confidence intervals (CI) were obtained
from Cox regression models adjusted for age group,
FIGO stage, histologic subtype and grade. The TCGA
dataset was adjusted for age, FIGO stage and histologic
grade, but not subtype because all the samples were
of the serous subtype. For the combined analysis, a
weighted average of the log HR was calculated, taking
into account random effects using the method of DerSi-
monian and Laird [23]. Linkage Disequilibrium (LD)
maps were generated using Haploview 4.2 [24].
Results
Analysis of KLK15 transcripts
All of the published KLK15 mRNA variants [25] were
collated from GenBank (Figure 1A). Six isoforms were
observed. The classical form, isoform 4 (NM_017509),
has five exons and encodes a protein of 256 amino acids
(aa). However, this was recently extended to include an
additional 5’ untranslated exon (exon A) discovered
from an EST clone (CF139951). Another 3 known iso-
forms (1-3) encode 3 different length proteins of 122aa,
161aa and 171aa respectively. Isoform 5 (AY373373)
and isoform 6 (AY373374) both encode proteins of
1 6 2 a a ,s i n c et h e ys h a r et h es a m es t o pc o d o na tt h e
beginning of intron 3; the additional loss of exon 4 for
isoform 6 does not affect protein length (Figure 1A).
Isoform 5 was found to form the most stable secondary
structure based on ΔG values predicted by mfold, while
isoform 3 was the least stable (data not shown).
We also identified an additional KLK15 splice variant
from the three new EST clones (GenBank accession No.
BP428687, BP431267, BP431386). This new isoform has
a novel exon between exon A and exon 1, that we have
n a m e de x o nB .E x o nBi sl o c a t e d1 5 7 5b pu p s t r e a m
from exon 1, however all three EST clones show that
exon B is spliced onto exon 2, skipping exon 1 (Figure
1A). The longest clone encodes a protein that is 106 aa
long, shorter than that observed for the other isoforms;
however it does not contain a stop codon and therefore
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Using SignalP 3.0 Server and PSORT II, the exon B var-
iant was not predicted to contain a possible cleavage
site for an N-terminal signal peptide, thus is most likely
to be an intracellular protein. In contrast, the other iso-
forms all are predicted to have signal peptides and a
predominantly cytoplasmic and extracellular localization
as expected for secreted proteins. The exon B variant
was confirmed by RT-PCR in serous ovarian epithelial
cancer cell lines PEO1 and OVCA432 and also in the
prostate cancer LNCaP cell lines (Figure 1B).
In silico promoter analysis to prioritize regions for
sequencing and SNP modeling
Cister and JASPAR together identified 30 putative Andro-
gen Response Elements (AREs) (15 upstream of exon A, 1
in exon A, 8 between exon A and B, 2 in exon B, and 4
b e t w e e ne x o nBa n d1 ) .O n l y2A R E s( F i g u r e2 A )w e r e
predicted by both tools (1 upstream of exon A and the
other between exon B and exon 1). Dragon ERE finder
and Cister predicted 30 putative Estrogen Response
Elements (EREs) upstream of exon 1 (17 upstream exon
A, 9 between exon A and B, and 4 between exon B and 1).
Four EREs (Figure 2A) predicted by Dragon ERE finder
overlapped an ERE predicted by Cister. Cister identified
two clusters of cis-elements (Figure 2A), both upstream of
exon A. The first cluster starts 4232 bp upstream of exon
A, spans 467 bp and contains eight putative cis-elements.
The second cluster starts 2108 bp upstream of exon A,
spans 1892 bp and contains 10 putative cis-elements. Two
putative promoter regions on the forward strand were
detected using WWW Promoter Scan The first putative
promoter is 189 bp downstream of exon A and spans 250
bp, and the second is 852 bp downstream of exon A and
spans 252 bp. PromoterInspector detected one putative
promoter region which is 992 bp downstream of exon A
and spans 463 bp. CpGPlot showed three putative CpG
islands with a percent C+G of above 50%, observed/
expected ratio of above 0.60 and a length of over 100 bp:
the first is 4519 bp upstream of exon A and spans 115 bp;
the second is 538 bp downstream of exon A and spans
1 0 6b p ;t h et h i r di s7 7 8b pd o w n s t r e a mo fe x o nAa n d
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Figure 1 Diagrammatic representation of human KLK15 mRNA transcripts and confirmation of the exon B variant by RT-PCR. (A) Various
isoforms (1-6) of KLK15 derived from the NCBI database are shown with the two new isoforms identified from the EST database containing novel
exons, A and B, highlighted in red boxes. The unshaded boxes represent the noncoding exons, shaded black boxes for the isoforms represent the
coding exons and the connecting lines the introns. Numbers inside boxes or above connecting lines represent exon or intron lengths in base pairs
respectively. H, denotes histidine; S, denotes serine; and D, denotes aspartate [amino acids of the catalytic triad of the (putative) encoded proteins].
The arrowhead points to the common start codon and astericks (*) to the stop codon positions. (B) PCR was conducted on the cDNA from five
different cell lines HOSE17.1 (1), PEO1 (2), OVCA432 (3), SKOV3 (4), LNCaP (5) and no cDNA (6) using the Forward primer in exon B and reverse
primer in exon 2. Two products were obtained corresponding to with (144 bp) and without (70 bp) exon 1.
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putative promoters found by WWW Promoter Scan and
PromoterInspector (Figure 2A).
SNP information and prediction of functional effects
Gene
A total of 76 (27 validated) SNPs in the exonic-intronic
region of KLK15 were retrieved from the NCBI dbSNP
database, comprising 10 exonic SNPs (4 non-synonymous,
1 synonymous and 5 in 3’ UTR) (Additional file 4) and 66
intronic SNPs (data not shown). Although predicted to be
damaging by FastSNP, SIFT and PolyPhen predicted that
the validated non-synonymous (ns) exonic SNPs were
unlikely to have any deleterious effect on protein structure
(Additional file 4). FastSNP server predicted that the
synonymous (s) SNP and the 3’ UTR SNPs were not
damaging with a risk score of 0-1 (Additional file 4). The
rs3212852 SNP present at the 3’ end of exon 3 was pre-
dicted to have a damaging effect with a medium-high risk
score of 3-4. No damaging scores were observed for the
B
56,026591
A
56037591                                        56032281         56032183                                 56028255         56028167             56026591
Figure 2 The putative KLK15 promoter region: (A) The 11 kb region upstream of exon 1 on chromosome 19 (56020307 to 56037591 bp,
NCBI build 36.3) was downloaded for in silico analysis (A) schematic of the 5’ region of the KLK15 gene with significant motifs noted: 2 putative
Androgen Response Elements (AREs) were found by both JASPAR and Cister programs (red arrows); 4 putative Estrogen Response Elements
(EREs) were found by both ERE finder and Cister programs (blue arrows); 2 putative cis-element clusters which indicate putative promoter
regions found by Cister (green arrows); 2 putative promoter regions that overlap with CpG islands found by WWWPromoter Scan, Promoter
Inspector and CpG Island Finder (yellow arrows) (B) AREs (boxes), EREs (triangle) and Nuclear Hormone Receptor Binding Sites (NHRBs) (circles) as
predicted by individual softwares. The ARE “cluster” consists of 16 AREs. The colored bars (blue, red, green, orange, yellow) in the sequence
indicate the 5 regions that were chosen for sequencing genomic DNA. The single nucleotide polymorphism (SNP)-modeling results are shown
by color coding the functional SNPs validated in bold. Orange and red text coloring indicate a gain or loss of ERE motifs respectively, while
green and blue indicate ARE gain or loss. The two brown SNPs indicate a loss of one ERE and a loss of two AREs. An additional four validated
SNPs viz rs2659052, rs11880663, rs2659051, rs2659055 have been added to NCBI databases (not modeled here) from the time of our analysis.
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intron boundaries. We also predicted miRNA binding
sites using three different software programs; Target Scan,
miRanda and Patrocles. A maximum of 32 miRNA bind-
ing sites scattered throughout the gene were predicted by
miRanda (data not shown). Interestingly, the 3’UTR SNP
rs3212810 lies in the target sequence of mir-498, which
has been reported to be dysregulated in prostate cancers
[26]. Also, rs3212853 was predicted to be a potential poly-
morphic miRNA target site (using Patrocles target data-
base), where the presence of the mutant allele creates a
binding site for miR-193b (Additional file 4), shown to be
involved in tumor progression and invasion in human
breast cancer [27] and a tumor suppressor in prostate
cancer [28].
Promoter
As gene expression may be influenced by promoter
polymorphisms, we included analysis of SNPs in the 11
kb upstream region from exon 1 and found 62 (out of
the total 101) validated SNPs. In silico analysis predicted
that 8 SNPs created a new putative ERE/ARE site while
10 other SNPs were predicted to destroy one or more
putative ERE/ARE sites using two different software
programs; JASPAR and Cister for the ARE and Cistor
and Dragon ERE finder for the ERE (Figure 2B).
Further, it was observed that 22 SNPs created one or
more new transcription factor binding sites (TFBS)
while 25 SNPs completely lost one or more TFBS as
predicted by Genomatrix ElDorado program (data not
shown).
Promoter sequencing of cancer cell lines and aggressive
cancer patients
To confirm the polymorphic status of reported SNPs and
identify novel SNPs with potential prognostic significance,
we sequenced genomic DNA within the KLK15 promoter
(Figure 2B) of four ovarian (normal -HOSE17.1; cancer-
OVCA432, SKOV3 and PEO1) cell lines and the germline
DNA of 30 ovarian cancer patients with aggressive disease.
Sequencing analysis of the cell lines validated 15 SNPs,
including 6 non-validated SNPs in the NCBI database
(Additional file 5). Sequencing of genomic DNA from
aggressive ovarian cancer patients validated additional 5
SNPs (Additional file 5), and identified two novel SNPs
that were not predicted to be functionally relevant. Seven
SNPs from the NCBI database were found to be non-poly-
morphic in our sequencing cohort. The putative functional
role of the promoter SNPs is provided in Additional file 5.
LD mapping and SNPs selection for survival studies
SNPs chosen for genotyping in this study were (i) identi-
fied as tagging SNPs using HapMap version 22 (April
07), using a minor allele frequency >0.05 and pairwise
linkage disequilibrium threshold of r
2 > 0.8 (rs2659058,
rs3212810, rs3745522, rs2659056, rs266851, rs2163861,
rs266856), or (ii) chosen due to the above reported in
silico prediction of functional effect on KLK15 expression
(rs3212853, rs3212852, rs16987576, rs2659055, rs266853,
rs266854, rs190552, rs266855, rs2739442, rs2033496,
rs12978902, rs2659053, rs2569746, rs35711205,
rs2569747) (Table 1). As the frequency data for many of
these SNPs were not available, we genotyped all 22 SNPs
in controls and generated the LD map using Haploview
4.2 (Batra et al, unpublished data; Additional File 6). All
SNPs except rs3745522 were found to follow Hardy-
Weinberg equilibrium (p < 0.01). SNP rs12978902 was
non-polymorphic, while rs3212853, rs3212852,
rs16987576 rs266853 and rs266854 were found to have
minor allele frequencies < 0.05 (Table 1), so were not
pursued further for the survival analysis. SNPs in high
LD with other SNPs (r
2 > 0.9) were also not pursued
further. Priority was given to putative functional SNPs,
with a total of 12 SNPs shortlisted for further analysis
(Table 1). Three of these SNPs (rs2659056, rs266855 and
rs35711205) could not be genotyped in ovarian cancer
samples because of assay incompatibilities.
Association with ovarian cancer survival
Among the 319 Australian women with ovarian cancer,
188 (59%) died from the disease during the follow-up
period, with a 5-year survival proportion of 45%. Selected
clinical and pathologic characteristics of the Australian
women and the women in the two independent datasets,
the UK GWAS and TCGA, are shown in Table 2.
Among the Australian women a little over three quarters
were older than ≥50 years at diagnosis (77%), and many
presented with late stage disease (71%), tumors of high
grade (54%) and serous histological subtype (64%). In the
U KG W A Sd a t a s e tm o s tw o m e nw e r e≥50 years at diag-
nosis (78%), just over half the group had early stage dis-
ease (56%) and serous histological subtype (54%). The
TCGA dataset comprised women who were mostly older
than ≥50 years at diagnosis (79%), and the majority had
late stage (95%), high grade (88%) disease and all were of
serous histologic subtype.
SNP rs266851 showed statistically significant evidence
for an association with worse survival (Table 3) in the Aus-
tralian dataset. Increased risk was observed for the hetero-
zygote genotype CT (HR 1.43, 95% CI 1.02-2.00), and also
for the rare (2% of sample) homozygote genotype (HR
1.26, 95% CI 0.49-3.24); p trend = 0.01. Overall association
under a dominant model was HR 1.42 with 95% CI = 1.02-
1.96 (Table 3). This SNP was not found to be associated
with ovarian cancer stage (p = 0.41) or grade (p = 0.39)
(Table 2). None of the other SNPs investigated were asso-
ciated with ovarian cancer survival in Australian dataset.
In an attempt to replicate our results, we analyzed
genotype data obtained from the UK GWAS and the
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a similar direction of association in both the datasets for
the dominant model (HR 1.07, 95% CI 0.94 -1.24 in UK
GWAS data and HR 1.20, 95% CI 0.90-1.61 in TCGA
data) (Table 4). Combining the results of these two stu-
dies (UK GWAS and TCGA data) with our data gave a
summary HR of 1.16 (95% CI 1.0-1.35) for the SNP
rs266851 under a dominant model (Table 4).
Putative functional elements associated with SNP
rs266851
The rs266851 SNP is predicted to have a FastSNP score
= 0 in our initial analysis. As the FastSNP algorithm is
weighted by the SNP position with respect to gene
structure, and our data shows that rs266851 SNP is
l o c a t e d1 5b p3 ’ of a novel exon B, we used ESEfinder
[29] to predict the putative role of rs266851 SNP in
mRNA splicing. ESEfinder prediction suggests loss of
various SRp binding sites in the presence of T allele
(Additional file 7), thus this SNP could be involved in
alternative mRNA splicing.
Our preliminary unpublished data (Lai et al., personal
communication) suggest that exon B could be an alter-
native transcription start site (data not shown). Thus,
using the TFbind webtool [30], we predicted that the
C to T change may abrogate the binding site for Heat
Shock Factor 2 (HSF2), which activates expression of
Heat Shock Proteins (HSP), which have been shown to
play a vital role in tumorigenesis [31,32].
Discussion
With the completion of the human genome project, an
enormous amount of data has been generated and been
made available to the research community through var-
ious database repositories. At the same time many
bioinformatic/in silico tools have been made available to
extract data and help conceptualize future studies. To
our knowledge, this is the first study to use a compre-
hensive in silico approach for genetic data mining and
regulatory region identification to direct SNP prioritiza-
tion studies of the KLK15 gene and to analyze the asso-
ciation of KLK15 polymorphisms with ovarian cancer
survival.
In our efforts to delineate the functional significance
of the exonic SNPs, we used the Polyphen and SIFT
algorithms which showed minimal associations of SNPs
with likely functional amino-acid replacements. We thus
proposed that SNPs in regulatory regions can act in cis
Table 1 SNP selection for the survival studies
SNP no Name Rationale Position ObsHET PredHET HWpval MAF
1 rs2659058 Tagged SNP from HapMap 56017918 0.421 0.443 0.0869 0.331
2 rs3212810 Tagged SNP from HapMap and predicted to fall in miRNA binding site 56020548 0.364 0.369 0.6072 0.244
3 rs3212853 Ploymorphic miRNA target site 56020606 0.044 0.041 0.2863 0.037
4 rs3212852 Exon-Intron boundary 56021941 0.038 0.038 1 0.019
5 rs3745522 Tagged SNP from HapMap 56022744 0.349 0.383 0.0013 0.259
6 rs2659056 Tagged SNP from HapMap 56027755 0.383 0.382 1 0.257
7 rs266851 Tagged SNP from HapMap 56028151 0.297 0.306 0.2742 0.189
8 rs16987576 2 bp 3’ of exon B, Imp for splicing 56028165 0.003 0.003 1 0.001
9 rs2659055 Predicted in silico to affect HRE 56029044 0.485 0.5 0.3033 0.49
10 rs2163861 Tagged SNP from HapMap 56029204 0.485 0.5 0.2841 0.489
11 rs266853 Predicted in silico to affect TFBS and HRE 56029520 0.001 0.001 1 0.001
12 rs266854 Predicted in silico to affect HRE 56029630 0.004 0.004 1 0.002
13 rs190552 Predicted in silico to affect TFBS and HRE 56030005 0.333 0.346 0.1823 0.222
14 rs266855 Predicted in silico to affect HRE 56030196 0.396 0.413 0.1259 0.292
15 rs266856 Tagged SNP from HapMap 56030318 0.333 0.349 0.1131 0.225
16 rs2739442 Predicted in silico to affect TFBS and HRE 56030985 0.479 0.493 0.2975 0.442
17 rs2033496 Predicted in silico to affect TFBS and HRE 56031019 0.49 0.493 0.8309 0.442
18 rs12978902 Predicted in silico to affect HRE 56031056 0 0 1 0
19 rs2659053 Predicted in silico to affect TFBS and HRE 56032606 0.449 0.472 0.0722 0.382
20 rs2569746 Predicted in silico to affect TFBS and HRE 56032727 0.462 0.487 0.0638 0.42
21 rs35711205 Novel SNP (reported later in NCBI) 56032818 0.296 0.309 0.1212 0.191
22 rs2569747 Predicted in silico to affect TFBS and HRE 56032875 0.459 0.487 0.0346 0.419
ObsHet: Observed heterozygous alleles; PredHET: Predicted heterozygous alleles; HWpval: Hardy-Weinberg equilibrium p value; MAF: Minor allele frequency; HRE:
Hormone Response Element; TFBS: Transcription Factor Binding Site.
SNPs in the KLK15 gene derived from the HapMap database and those by in silico prediction methods were genotyped in control individuals, and the minor
allele frequency (MAF) and HWE were calculated using Haploview 4.2. SNPs in bold were shortlisted for genotyping and survival analysis on the basis on LD
calculations.
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order to identify the KLK15 promoter-regulatory region,
multiple alignments of all the KLK15 splice variants and
ESTs available in databases identified a novel isoform
with a new exon (termed exon B), upstream of exon 1.
This isoform utilizes exon B instead of exon 1 and is
predicted to have a different function by encoding a
protein lacking a signal peptide. Alternative KLK tran-
scripts may possess both physiological and prognostic
significance and some are emerging candidate biomar-
kers [25,33,34]. For example, the PSA-RP2 [35] and
KLK15 isoform 3 [11,36] are upregulated in prostate
cancer compared with benign prostatic hyperplasia tis-
sues suggesting that differential mRNA splicing may be
an important regulatory event in carcinogenesis. Thus,
the novel exon B variant identified by this study needs
to be explored further to assess its biological function
and prognostic significance, and such studies are under-
way in our laboratory.
In order to assess the role of common genetic variation
in altered regulation of KLK15, and with the knowledge
that steroid hormones have been implicated in the etiol-
ogy and/or progression of epithelial ovarian cancer [3],
we analyzed the in silico recognized promoter regions for
putative AREs and EREs. Though the results varied using
different databases, overlapping predictions suggested the
gain/loss of AREs and EREs in this region. We thus prior-
itized and confirmed the polymorphic status of the SNPs
in this region by sequencing genomic DNA from four
ovarian cell lines and 30 ovarian cancer patients. Of these
putative functional and HapMap tag SNPs selected for
genotyping, rs266851 was found to be associated with
poor overall survival in ovarian cancer in the Australian
cohort, The results were not found to be statistically
Table 2 Summary of clinical and pathological factors in
the Australian, UK GWAS and TCGA ovarian cancer
datasets
Australian
dataset
UK GWAS
dataset
TCGA
dataset
n* (%) n* (%) n* (%)
Age group
<40 21 (7) 97 (5) 7 (2)
40-49 51 (16) 316 (17) 74 (19)
50-59 85 (26) 653 (36) 123 (31)
60-69 99 (31) 594 (33) 97 (24)
70+ 63 (20) 155 (9) 96 (24)
FIGO stage
I 54 (18) 586 (44) 8 (2)
II 35 (11) 162 (12) 12 (3)
III 192 (63) 507 (38) 312 (79)
IV 26 (8) 80 (6) 65 (16)
Histological grade
well differentiated 41 (14) 239 (18) 2 (1)
moderately
differentiated
94 (32) 418 (32) 44 (11)
poor/undifferentiated 156 (54) 643 (50) 344 (88)
Histological subtype
serous 199 (64) 867 (54) 397 (100)
endometrioid 35 (11) 200 (13)
mucinuous 23 (8) 320 (20)
clear cell 21 (7) 173 (11)
other 32 (10) 40 (2)
*Numbers may not sum to total due to missing data.
Table 3 Association between KLK15 Single Nucleotide
Polymorphisms and ovarian cancer survival in Australian
dataset
KLK15 n n
censored
Adjusted* HR (95%
CI)
p value
(trend)
rs2659058
TT 123 74 1.0
CT 138 88 1.13 (0.82-1.55) 0.75
CC 50 26 1.20 (0.75-1.91)
rs3212810
CC 207 122 1.0
TC 87 51 1.01 (0.72-1.41) 0.29
TT 18 14 1.46 (0.82-2.62)
rs3745522
GG 187 106 1.0
GT 81 48 0.97 (0.68-1.39) 0.15
TT 18 13 1.73 (0.93-3.24)
rs266851
CC 222 128 1.0
CT 89 55 1.43 (1.02-2.00)
TT 7 5 1.26 (0.49-3.24) 0.01
CT/TT 96 60 1.42 (1.02-1.96)
rs2659055
TT 84 52 1.0 0.23
TC 144 87 0.86 (0.60-1.23)
CC 67 36 0.74 (0.47-1.17)
rs190552
TT 178 109 1.0 0.79
CT 114 65 1.04 (0.76-1.42)
CC 19 13 1.21 (0.67-2.17)
rs2739442
GG 92 55 1.0 0.99
GA 133 76 1.09 (0.75-1.58)
AA 89 54 1.08 (0.73-1.62)
rs2659053
GG 129 79 1.0 0.2
GA 118 73 0.93 (0.66-1.29)
AA 63 34 0.95 (0.63-1.44)
rs2569746
AA 111 65 1.0 0.43
TA 119 74 0.90 (0.64-1.27)
TT 57 36 1.12 (0.74-1.69)
*Adjusted for age, FIGO stage, histological subtype, and grade.
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were similar in magnitude and direction to that of Aus-
tralian dataset. This is what might be expected for “win-
ner’s curse” phenomenon, where the estimated effect of a
marker allele from the initial study reporting the associa-
tion is often exaggerated relative to the estimated effect
in follow-up studies. The difference in magnitude of risk
estimates may also be partially explained by different case
ascertainment criteria. In particular, follow-up of the
large majority of the UK GWAS dataset was initiated at
least 6 months after diagnosis through the cancer regis-
try, biasing against recruitment of ovarian cancer cases
with short-term survival after diagnosis, and resulting in
a dataset that included more women with early FIGO
stage disease (56% vs. 21% FIGO stage I and II) and fewer
women diagnosed with serous ovarian cancer (47% vs.
66%). Consequently the 5-year survival rate was much
higher in the UK GWAS dataset (77% compared to 45%
for the Australian dataset), and it is interesting to note
that the UK dataset showed the risk estimate of lowest
magnitude (HR = 1.07). In contrast, the TCGA dataset
with similar characteristics to the Australian dataset
showed a risk estimate of greater magnitude (HR = 1.20),
although still not as great as the initial risk estimate
observed for the Australian dataset (HR 1.42). The overall
pooled HR of 1.16 observed for the dominant model in
our combined analysis is consistent with an association
between rs266851 SNP and ovarian cancer survival in
Australian dataset, and it would be important to confirm
these findings in a larger sample set of incident cases.
Interestingly, the rs266851 SNP was found to be asso-
ciated with an increased risk of breast cancer in the Can-
cer Genetics Markers of Susceptibility (CGEMS) project
Breast Cancer GWAS [37] with a trend p value = 0.008;
heterozygote risk = 1.22 (1.05-1.41); homozygote risk =
1.49 (1.11-2.00) (cases N = 1145, controls N = 1142).
So far no other SNP has been found to be in complete
LD with rs266851 from HapMap and next generation
sequencing data. Using in silico analysis, we predicted
that rs266851 could potentially be involved in differen-
tial mRNA splicing as the mutant allele was found to
abrogate the binding site for the SRp55 and SF2/ASF
splicing factors. There are several reports of elevated SR
protein family expression associated with ovarian cancer
[38] and SF2/ASF, specifically, has been described as a
proto-oncogene [39]. We also propose that rs266851
m i g h tb ei n v o l v e di nr e g u l a t i o no fKLK15 transcription
by altering the HSF-2 binding site. Recently an HSF-2
binding site has been detected in the KLK5 and KLK7
promoter-regulatory regions and their expression has
been found to correlate with HSF-2 expression in
microarray analysis of breast malignancies [40]. Never-
theless, more experimental evidence is required to
understand the effects of this variant on KLK15 expres-
sion and/or splicing.
Conclusions
This study supports a role of the KLK15 gene in ovarian
cancer by providing suggestive evidence for an associa-
tion of the rs266851 SNP with ovarian cancer survival.
The location of this SNP adjacent to a novel exon B and
in putative HSF2 and SRp binding sites should provide
impetus for downstream functional assays and additional
independent validation studies to assess the role of
KLK15 regulatory SNPs and KLK15 isoforms with alter-
native intracellular functional roles in ovarian cancer
survival. Our study also has applicability to studies
investigating the role of KLK15 genetic variation in
other hormone-related cancers, namely prostate, endo-
metrial and breast cancer.
Additional material
Additional file 1: Access information for KLK15. Information for KLK15
gene and its protein product was obtained from different databases and
is outlined in the additional file1.
Additional file 2: In silico promoter and SNP analysis. Additional file 2
details the different websites and software used to scan the promoter
region of KLK15 and to predict the functional significance of single
nucleotide polymorphisms in and around the gene.
Additional file 3: Primer sequences. Additional file 3 details the primer
sequence used for sequencing the KLK15 promoter region
Additional file 4: KLK15 intragenic SNPs and the results of in silico
analysis. Additional file 4 details the SNPs in KLK15 exon and exon Intron
boundary and the results of in silico analysis on these SNPS.
Table 4 Results of ovarian cancer survival analysis for the
KLK15 rs266851 SNP in Australian, UK GWAS data, TCGA
data and the combined datasets
KLK15 rs266851 n n censored Adjusted* HR (95% CI)*
Australian
CC 222 128 1.0
CT/TT 96 60 1.42 (1.02-1.96)
UK GWAS**
CC 1139 390 1.0
CT/TT 676 221 1.07 (0.94-1.24)
TCGA***
CC 280 135 1.0
CT/TT 133 76 1.20 (0.90-1.61)
Combined Analysis
CC 1641 653 1.0
CT/TT 905 357 1.16 (1.00-1.34)
*Adjusted for age, FIGO stage, histological subtype, and grade.
**The UK GWAS dataset was adjusted for age, FIGO stage, histologic subtype,
grade and study site.
***The TCGA dataset was adjusted for age, FIGO stage and histologic grade,
but not subtype as all the samples were of the serous subtype.
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Page 9 of 11Additional file 5: Validated KLK15 promoter SNPs. SNPs validated by
KLK15 promoter sequencing of genomic DNA from ovarian cell lines and
aggressive patients and their predictive functional role.
Additional file 6: Linkage Disequilibrium map generated by
Haploview 4.2. Frequency data was generated for the control individuals
and the LD map was plotted. SNPs not in bold were found to have
frequencies < 0.05.
Additional file 7: Prediction of functional role of the rs266851 SNP.
ESE Finder Matrices analysis for SRp40, SC35, SF2/ASF and SRp55 splicing
proteins.
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